Fawzi Abu Rous, Thoracic Medical Oncologist at the Henry Ford Health, shared a post on LinkedIn:
“Grateful to share my interview with the Oncology Learning Network about our recent case report published in Clinical Lung Cancer.
We discussed a patient with BRAF V600E–mutated small cell lung cancer who has had a durable response to dabrafenib plus trametinib since 2021 — a rare and encouraging outcome in SCLC.
This case highlights why molecular testing should not be overlooked, even in historically non-targetable cancers.”
More posts featuring Fawzi Abu Rous.